Navigation Links
Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
Date:12/1/2009

. PL-3994 has an extended half-life, with reduced affinity for natriuretic peptide clearance receptors and increased resistance to neutral endopeptidase, an endogenous enzyme that degrades natriuretic peptides. The result is a drug candidate with improved pharmacokinetic and pharmacodynamic properties.

About Heart Failure

Heart failure affects over 5.7 million people in the United States, with 670,000 new cases diagnosed each year. Despite the treatment of heart failure with multiple drugs, the prognosis remains poor. There were over 1.1 million hospitalizations for heart failure in 2006 in the United States, with estimated direct and indirect costs of heart failure in the United States for 2009 of $37.2 billion.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.

Forward-looking Statements

Statements about future expectations of Palatin Technologies, Inc., including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereb
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
2. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
3. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
4. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
5. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
6. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
9. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
10. Palatin Technologies Receives Notification Letter from NYSE Alternext US
11. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... ... regulatory compliance, quality systems, analytical testing, education and consulting services for the ... in medical device products/processes development, design control, validation, quality assurance and regulatory ...
(Date:9/2/2015)... ... 2015 , ... The wet form of macular degeneration, although ... growth factor agents given by injection into the eye. Dry macular degeneration (AMD) ... for the many millions diagnosed with it. AMD usually starts in older age ...
(Date:9/2/2015)... , Sep. 02, 2015 ... http://www.researchandmarkets.com/research/bvxxkf/cytogenetics ) has announced the addition of ... Technologies, Markets and Companies" to their ... includes several technologies besides fluorescence in situ ... multicolor FISH. Molecular cytogenetics includes application of ...
(Date:9/2/2015)... Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., announced ... the multicenter Phase 2 clinical trial of NT-503 ... of recurrent subfoveal choroidal neovascularization secondary to age ... unique vascular endothelial growth factor (VEGF) receptor protein ... "This landmark proof-of-concept study will evaluate NT-503 ...
Breaking Biology Technology:NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4
(Date:8/5/2015)... -- According to a new market research ... Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, Defense ... 2020", published by MarketsandMarkets, defines and segments the Physical ... The global PIAM Market is estimated to grow from ... at a CAGR of 14.9 % from 2014 to ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:8/4/2015)... Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today reported ... 2015. Highlights: , Second quarter contract revenue ... 2014 , Adjusted contract margins of ... $0.22, including a $0.05 decrease in EPS from royalties in the ... million "We are very pleased to present another ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... Chris Field, professor of interdisciplinary environmental studies at Stanford ... (IPCC) Fifth AssessmentWorking Group II. WHAT: ... change that isfaster than at any time in the last ... on the topic. WHEN: Friday, Feb. ...
... Council (MRC) has announced 580,000 of funding to facilitate ... capacity in Africa focused on the health effects of ... identified as a major preventable cause of disease and ... The BREATHE Africa partnership (Biomass Reduction and Environmental ...
... society devoted to furthering research aimed at the understanding proteins, ... awards will be conferred at the 28th Annual Symposium of ... Plenary talks from each recipient are scheduled throughout the 3.5 ... by Rigaku Corporation, is given to an outstanding protein scientist ...
Cached Biology News:MRC funds BREATHE Africa partnership 2The Protein Society announces its 2014 award recipients 2The Protein Society announces its 2014 award recipients 3
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
... a thermostable DNA polymerase purified from the ... procedures developed by Kaledin (1,2,3) for the ... activity from thermophilic bacteria. Amplification of DNA ... achieved with this enzyme. The enzyme has ...
... to Cytokeratin 5 / 6 Cytokeratin ... weight, basic type of cytokeratin expressed in ... layers of stratified epithelia as well as ... cells and mesothelioma. Cytokeratin 6 (56 kD) ...
Aldolase A (N-15)...
Biology Products: